Araceli Bio

Coming – August 26

Accelerating Drug Discovery With Game-Changing Imaging Technology

Date and Time

August 26

–

12:00 PM ET 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Araceli Biosciences is poised to become the backbone of next-generation drug discovery and AI-driven therapeutics.

Demand for faster, AI-compatible imaging systems is accelerating across all of pharma—making this a timely and rare opportunity.

Araceli is solving a major bottleneck in biotech: today’s cellular imaging technologies simply can’t keep up with the scale, speed, or complexity required for advanced drug screening, AI model training, or novel CRISPR-based discovery. Araceli’s ultra-high-throughput platform is built on patented hardware, optimized software, and intelligent informatics. It is more than 40x faster than existing systems and already being adopted by top TechBio innovators.

The company is targeting three rapidly growing markets:
  • $1.4B+ high-content imaging market, where Araceli is on track to capture 10–15% share
  • $60M+ TechBio segment, growing at ~40% CAGR, where it holds a first-mover advantage as the only platform fast enough to meet modern demand
  • $1.6B+ market for the associated consumables

Araceli has paying customers in place including Bayer, Merck, Vertex, and Genentech. The company has multiple revenue streams including equipment sales, service contracts, software licenses, and consumables. Led by a seasoned team with prior biotech exits, Araceli is targeting a strategic liquidity event within 3–4 years.

Register now to join this webinar with Matt Beaudet, President and CEO of Araceli, to hear why the company offers a unique platform opportunity at the intersection of AI and biotech.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.